Objectives. One previous study has estimated the prevalence of pruritus in SSc, but that study had important limitations due to a relatively small sample size. The present study updates the analyses of the previous study using a substantially larger patient sample. The objectives were to (i) document the proportion of patients who experience pruritus on most days overall and by disease duration and (ii) identify clinical correlates of pruritus.
Introduction
SSc or scleroderma is a chronic autoimmune connective tissue disorder characterized by abnormal fibrotic processes and excessive collagen production that manifests itself in fibrosis of the skin and internal organs such as the lungs, kidneys and gastrointestinal tract [1] . Pruritus, or itch, is associated with reduced mental and physical functioning in SSc [2] , but only one previous study has assessed the prevalence and clinical correlates of pruritus in SSc [3] . In that study, 45% of 400 patients with a disease duration of at least 1 year reported pruritus within the last month, including 69% of 16 patients with a disease duration of 12 years. Pruritus was significantly associated with gastrointestinal symptoms. A limitation of that study was the relatively small number of patients with pruritus, particularly in more recently diagnosed patients.
The present study is an update of the analyses reported in the previous study, using a much larger sample of SSc patients. The objectives of the present study were to (i) document the proportion of patients with pruritus on most days in the past month overall and in subgroups defined by disease duration, (ii) assess the stability of pruritus over time by comparing the proportion of patients who reported having pruritus at two consecutive registry visits 1 year apart, and (iii) identify sociodemographic and disease factors associated with the presence of pruritus.
Methods

Patient sample
The study sample consisted of patients enrolled in the Canadian Scleroderma Research Group (CSRG) Registry who completed their first and second annual follow-up visits and at each visit responded to an item, described below, assessing the presence of pruritus on most days in the past month. Patients in the present study included the 400 patients from the previous report as well as additional patients who entered the registry subsequently. An item assessing the presence of pruritus is administered at all follow-up visits, but not at the initial baseline registry visit. Patients in the registry were recruited from 15 centres across Canada. To be eligible for the registry, patients must have a diagnosis of SSc made by the referring rheumatologist, be 518 years of age, and be fluent in English or French. Registry patients undergo an extensive clinical history, physical evaluation, and laboratory investigations and complete a series of self-report questionnaires. The CSRG Registry and this study were approved by the Research Ethics Committee of McGill University. All patients provided informed written consent for the CSRG Registry.
Measures
In addition to the presence or absence of pruritus, analyses included sociodemographic variables and disease variables.
Pruritus
The presence of pruritus was evaluated with a dichotomously scored item (no/yes), 'I have or I have had in the past month itchiness in my skin, on most days'. Similar questions have been used to establish the prevalence of pruritus in dermatological diseases [4] , and the same item was used to assess the presence of pruritus in the previous study in SSc [3] .
Disease-related variables
SSc disease duration was defined as the time from onset of the first non-Raynaud's symptom based on the clinical history obtained by study rheumatologists. As in the previous study, rates of pruritus were reported across disease duration [5] . Skin involvement was assessed using the modified Rodnan skin score (range 051) [5] . Limited skin disease was defined as skin involvement distal to the elbows and knees with or without facial involvement while diffuse skin disease was defined as skin involvement proximal to the elbows and knees and/or involving the trunk. The tender joint count was recorded by study physicians using a 28-joint count [6] . Physician-recorded history of SSc renal crisis was used. Unlike the previous study [5] , in which patient-reported variables were used, disease severity was measured using the modified Medsger Scleroderma Disease Severity Scale [7, 8] . In addition, serum was collected on all patients and sent to the central laboratory at the Advanced Diagnostics Laboratory at the University of Calgary, Calgary, Alberta, Canada. Aliquots of sera are stored at À70 C until needed. Anti-nuclear and anticentromere antibodies were assessed by indirect immunofluorescence on Hep-2000 substrate (ImmunoConcepts Inc., Sacramento, CA, USA) and antibodies to extractable cell antigens were assessed by addressable laser bead immunoassay using a commercial kit (QuantaPlex SLE Profile 8; INOVA Diagnostics, San Diego, CA, USA). An ELISA kit (INOVA Diagnostics) was used to detect antibodies to RNA polymerase III (anti-RNAP-III) [9] . The use of medications typically used for the treatment of scleroderma was recorded by study physicians.
Data analyses
Patients who reported pruritus at the first follow-up visit were compared with patients without pruritus on demographic and disease variables. Categorical variables were compared using the 2 statistic and continuous variables with two-tailed t-tests. To evaluate associations between sociodemographic and disease variables with pruritus we used hierarchical multiple logistic regression. Sociodemographic variables, including age, sex, marital status (married or living as married vs single/divorced/ widowed) and education (>high school vs high school or less) were entered in Step 1. Disease variables, including disease duration, Rodnan skin score, number of tender joints and modified Medsger gastrointestinal tract score were entered in Step 2. The discrimination and calibration of the models were assessed based on the c-index and the HosmerLemeshow (HL) goodness-of-fit test statistic, respectively [10] . Analyses were conducted using SPSS version 20.0 (Chicago, IL, USA) and statistical tests were two-sided with a P < 0.05 significance level.
Results
Study sample
Data on pruritus prevalence at the first follow-up visit were available for a total of 959 patients; this total sample size was used to calculate the overall prevalence of pruritus and the prevalence across disease duration. Sociodemographic and disease characteristics are shown in Table 1 . Of the 959 patients, 693 had complete data for first and second follow-up visits; this subsample was used to evaluate the stability of reports of pruritus over time. There were 871 patients with complete data on all sociodemographic and disease variables at the first follow-up visit; this subsample was used for the multiple logistic regression analysis to identify clinical correlates of pruritus.
Pruritus prevalence overall and by disease duration For the 693 patients with data at both visits, 48.0% (n = 333) reported pruritus at neither visit, 12.6% (n = 87) only the first visit, 9.2% (n = 64) only the second visit and 30.2% (n = 209) at both visits. The 693 patients with data at both visits were generally similar on sociodemographic and disease variables to the 266 patients with data only for the first visit, and the percentages of patients reporting pruritus in these two groups were nearly identical (42.7% of 693 patients and 42.5% of 266 patients; P = 0.948).
Clinical correlates of pruritus
Bivariate associations of sociodemographic and disease variables with pruritus are shown in Table 1 , with multiple logistic regression results in Table 2 . The presence of pruritus was independently associated with higher Rodnan skin scores [odds ratio (OR) = 1.02, 95% CI 1.00, 1.04, P = 0.017] and higher modified Medsger scores for the gastrointestinal tract (OR = 1.24, 95% CI 1.04, 1.48, P = 0.018). The model had adequate discriminative power (c-index = 0.70) and calibration (P = 0.642 for the HL statistic).
Discussion
The percentage of patients with scleroderma who reported pruritus on most days in the past month was 43%. There were no statistically significant or substantive differences by disease duration. Just under half of the patients in the study reported that they did not experience pruritus in either year this was assessed. Greater skin involvement and greater gastrointestinal involvement were independently associated with pruritus. The major difference between the present study and the previous study was that the previous study found a high rate of pruritus in early disease (69% of 16 patients with 1.01.9 years duration), possibly due to the small number of patients sampled.
In both SSc and other diseases where pruritus is a common feature, little is known about the short-term and long-term course of pruritus across the natural history of the disease. Recently a longitudinal study of uraemic pruritus in haemodialysis patients [11] assessed the presence of pruritus every 2 weeks for a 12-week period and reported that the pattern of pruritus in these patients was often cyclical. Research is needed to elucidate the trajectory of pruritus in SSc, as the natural history of pruritus will be an important factor in developing treatments. Recently a published case series of three SSc patients [12] suggested that low-dose naltrexone, an opioid receptor antagonist, may reduce symptoms of pruritus. A small number of randomized controlled trials have tested orally or topically administered opioid antagonists to treat pruritus in mixed skin disorders [13] , atopic dermatitis [13] , atopic eczema [14] , ureamic pruritus [15, 16] and cholestasis [17, 18] . The results from these trials have varied, but all have had very small sample sizes, with the largest studying a total of 40 patients [13] .
Several limitations should be considered in interpreting the results of this study. First, pruritus was measured with a dichotomous question and by self-report. It is possible, for instance, that although the proportion of patients with pruritus does not change substantially across time, the severity of symptoms could be different, and this would not be detected with the dichotomous assessment used in this study. Second, there were no patients in the first [19] . In summary, the current study found that 43% of patients with SSc reported pruritus on most days in the last month. The prevalence of pruritus did not change substantially across disease duration and appeared to be relatively stable within patients in that 58% of patients with pruritus during at least one visit reported pruritus at both visits. Controlling for sociodemographic and other disease characteristics, there were small but statistically significant associations of pruritus with skin involvement and gastrointestinal symptoms. Studies with prospective methodologies that examine pruritus across shorter time intervals, such as weeks or months, and with continuous measures of pruritus severity are required to better understand the natural history of pruritus in SSc.
Rheumatology key messages
. The prevalence of pruritus in SSc was 43%. . The prevalence of pruritus was generally stable across disease duration. . The presence of pruritus was associated with greater skin involvement and greater gastrointestinal involvement.
